Novorex, founded in 2020 and based in Seongnam, South Korea, is focused on developing GPCR-targeted small-molecule drugs using cutting-edge technology, including artificial intelligence. By combining biophysical analysis and in vitro/in vivo assays, Novorex aims to predict and verify small molecules that act on disease-targeting proteins. Their goal is to provide advanced treatment options for patients with cancer and central nervous system diseases, addressing areas such as neurological disorders, cognitive function, and cancer.